Early therapy-related myeloid sarcoma and deletion of 9q22.32 to q31.1. Pediatr Blood Cancer 2014 Sep;61(9):1701-3
Date
03/29/2014Pubmed ID
24668947DOI
10.1002/pbc.25040Scopus ID
2-s2.0-84904420991 (requires institutional sign-in at Scopus site) 2 CitationsAbstract
Survival following childhood neuroblastoma is improving with low rates of secondary myeloid neoplasms. We describe a 13-month-old male with intermediate risk neuroblastoma who developed an isolated scalp therapy-related myeloid sarcoma (t-MS). Developmental delays and two distinct malignancies prompted constitutional evaluation. Chromosomal microarray identified a 7.3 Mb deletion of 9q22.32 to 9q31.1. He remains in remission 11 months following hematopoietic cell transplant. Unusual presentations of rare diseases necessitate a multidisciplinary approach and adaptation of standardized protocols to accommodate increased risks imposed by genetic variants.
Author List
Brickler MM, Basel DG, Gheorghe G, Margolis DM, Kelly ME, Ehrhardt MJAuthors
Donald Basel MD Chief, Professor in the Pediatrics department at Medical College of WisconsinMolly Brickler NP APP Hybrid in the Pediatrics department at Medical College of Wisconsin
David A. Margolis MD Chair, Professor in the Pediatrics department at Medical College of Wisconsin
MESH terms used to index this publication - Major topics in bold
Chromosome DeletionChromosomes, Human, Pair 9
Combined Modality Therapy
Developmental Disabilities
Graft vs Host Disease
Humans
Infant
Male
Neoplasms, Second Primary
Neuroblastoma
Prognosis
Sarcoma, Myeloid
Secondary Prevention
